Primary endpoint analysis at 1 year showed better maintenance of erectile function and pad-free continence with TULSA than with robotic radical prostatectomy. Peri-procedural metrics favored TULSA, ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

TORONTO, March 27, 2026 (GLOBE NEWSWIRE)-- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, ...

TORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, ...

Arun Menawat, CEO of Profound Medical, talks about the company’s innovative TULSA-PRO technology. In a recent interview, Arun Menawat, CEO of Profound Medical, discussed the company’s innovative TULSA ...

Profound Medical (PROF) announced the launch of a TULSA program by Texas Prostate and Dallas Medical Center to meet the growing demand for advanced prostate treatment – without surgery. Under the ...

TULSA reduces tumor volume and PSA levels, improving urinary and sexual function in prostate cancer patients. Five-year TACT study data shows 80% of patients had no significant disease after one year, ...

Prostate cancer is the most common cancer and the second leading cause of death among men, the National Cancer Institute says ...

Bill Faulkner had long approached prostate cancer testing with skepticism. For almost a decade, the 73-year-old had avoided the prostate-specific antigen test because of concerns about over-diagnosis; ...